Wing N Chan

US Patent:

6920471, Jul 19, 2005

Filed:

Apr 16, 2002

Appl. No.:

10/123677

Inventors:

Wing K. Chan - Allen TX, US
Joseph T. Nabicht - Dallas TX, US

Assignee:

Texas Instruments Incorporated - Dallas TX

International Classification:

G06F017/10

US Classification:

708300

Abstract:

A simple, power efficient and inexpensive digital compensation scheme for reducing delay in a digital impedance matching circuit to improve return loss. The scheme employs a digital filter to compensate for the absolute sampling and digital delays associated with a digital impedance matching circuit. The digital filter is based on the low-pass function of a DAC response, and can easily be modified to correct for not only the DAC response delay, but also other delays in the digital impedance matching circuit. The digital filter is very simple to implement and can add or subtract delays from the overall system.

US Patent:

7062037, Jun 13, 2006

Filed:

Apr 30, 2002

Appl. No.:

10/137160

Inventors:

Wing K. Chan - Allen TX, US
Joseph T. Nabicht - Dallas TX, US

Assignee:

Texas Instruments Incorporated - Dallas TX

International Classification:

H04M 1/00
H04M 9/00

US Classification:

379394, 37939901, 37939902, 379400

Abstract:

A technique for implementing impedance matching circuits that use the transfer functions of each line impedance model. This technique allows implementation of an impedance match for a diverse number of line impedances reusing the same circuit topology, by simply adjusting coefficients to accommodate different line impedances.

US Patent:

20180237519, Aug 23, 2018

Filed:

Feb 22, 2016

Appl. No.:

15/552078

Inventors:

- Columbus OH, US
Wing Keung CHAN - Columbus OH, US
Jianhua YU - Columbus OH, US

International Classification:

C07K 16/28
A61P 35/00

Abstract:

A polypeptide is disclosed that binds tumor-associated antigens (TAA) on the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the surfaces of killer cells such as natural killer cells, T cells, natural killer T cells, and gamma delta T cells. In some cases, the TAA is CS-1 or EGFRvIII. Also disclosed are polynucleotides encoding the disclosed polypeptides, vectors comprising the disclosed polynucleotides, and host cells comprising the disclosed vectors. Also disclosed are bivalent antibodies comprising the disclosed polypeptides. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies. Also disclosed are methods of treating cancer in a subject using the disclosed bi-specific antibodies.